Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile

por Byrn, Stephen R., Tishmack, Patrick A., Milton, Mark J., van de Velde, Helgi
Publicado 2011

The influence of baseline characteristics and disease stage on health‐related quality of life in multiple myeloma: findings from six randomized controlled trials

por Robinson, Don, Esseltine, Dixie‐Lee, Regnault, Antoine, Meunier, Juliette, Liu, Kevin, van de Velde, Helgi
Publicado 2016

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling

por Gupta, Neeraj, Diderichsen, Paul M., Hanley, Michael J., Berg, Deborah, van de Velde, Helgi, Harvey, R. Donald, Venkatakrishnan, Karthik
Publicado 2017

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

por Bisht, Kamlesh, Fukao, Taro, Chiron, Marielle, Richardson, Paul, Atanackovic, Djordje, Chini, Eduardo, Chng, Wee Joo, Van De Velde, Helgi, Malavasi, Fabio
Publicado 2023

New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib

por Richardson, Paul G, Kumar, Shaji, Laubach, Jacob P, Paba-Prada, Claudia, Gupta, Neeraj, Berg, Deborah, van de Velde, Helgi, Moreau, Philippe
Publicado 2017

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

por Richardson, Paul G., Facon, Thierry, Bensinger, William I., Leleu, Xavier, Campana, Frank, Macé, Sandrine, Chiron, Marielle, van de Velde, Helgi, Mikhael, Joseph
Publicado 2021

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone

por Thai, Hoai‐Thu, Gaudel, Nadia, Cerou, Marc, Ayral, Geraldine, Fau, Jean‐Baptiste, Sebastien, Bernard, van de Velde, Helgi, Semiond, Dorothée, Veyrat‐Follet, Christine
Publicado 2021

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

por van Rhee, Frits, Casper, Corey, Voorhees, Peter M., Fayad, Luis E., van de Velde, Helgi, Vermeulen, Jessica, Qin, Xiang, Qi, Ming, Tromp, Brenda, Kurzrock, Razelle
Publicado 2015

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma

por Jin, Jie, Okamoto, Rumiko, Yoon, Sung-Soo, Shih, Lee-Yung, Zhu, Jun, Liu, Ting, Hong, Xiaonan, Pei, Lixia, Rooney, Brendan, van de Velde, Helgi, Huang, Huiqiang
Publicado 2018

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

por Koiwai, Kimiko, El‐Cheikh, Raouf, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean‐Baptiste, Veyrat‐Follet, Christine, Risse, Marie‐Laure, van de Velde, Helgi, Semiond, Dorothée, Nguyen, Laurent
Publicado 2021

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

por Martin, Tom, Richardson, Paul G., Facon, Thierry, Moreau, Philippe, Perrot, Aurore, Spicka, Ivan, Bisht, Kamlesh, Inchauspé, Marlene, Casca, France, Macé, Sandrine, van de Velde, Helgi, Suzuki, Kenshi
Publicado 2022

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

por Gupta, Neeraj, Hanley, Michael J., Diderichsen, Paul M., Yang, Huyuan, Ke, Alice, Teng, Zhaoyang, Labotka, Richard, Berg, Deborah, Patel, Chirag, Liu, Guohui, van de Velde, Helgi, Venkatakrishnan, Karthik
Publicado 2018

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myelom...

por Rachedi, Fatiha, Koiwai, Kimiko, Gaudel‐Dedieu, Nadia, Sebastien, Bernard, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean Baptiste, Nguyen, Laurent, van de Velde, Helgi, Veyrat‐Follet, Christine, Semiond, Dorothée
Publicado 2022

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

por Verhoef, Gregor, Robak, Tadeusz, Huang, Huiqiang, Pylypenko, Halyna, Siritanaratkul, Noppadol, Pereira, Juliana, Drach, Johannes, Mayer, Jiri, Okamoto, Rumiko, Pei, Lixia, Rooney, Brendan, Cakana, Andrew, van de Velde, Helgi, Cavalli, Franco
Publicado 2017

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

por Martin, Thomas G., Corzo, Kathryn, Chiron, Marielle, van de Velde, Helgi, Abbadessa, Giovanni, Campana, Frank, Solanki, Malini, Meng, Robin, Lee, Helen, Wiederschain, Dmitri, Zhu, Chen, Rak, Alexey, Anderson, Kenneth C.
Publicado 2019

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

por Garderet, Laurent, Laubach, Jacob P., Stoppa, Anne-Marie, Hari, Parameswaran, Cavo, Michele, Ludwig, Heinz, Mateos, María-Victoria, Luptakova, Katarina, Lin, Jianchang, Yung, Godwin, van de Velde, Helgi, Berg, Deborah, Moreau, Philippe, Richardson, Paul G.
Publicado 2018

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

por Martin, Thomas, Mikhael, Joseph, Hajek, Roman, Kim, Kihyun, Suzuki, Kenshi, Hulin, Cyrille, Garg, Mamta, Quach, Hang, Sia, Hanlon, George, Anup, Konstantinova, Tatiana, Risse, Marie-Laure, Asset, Gaelle, Macé, Sandrine, van de Velde, Helgi, Moreau, Philippe
Publicado 2022

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

por Dimopoulos, Meletios A., Leleu, Xavier, Moreau, Philippe, Richardson, Paul G., Liberati, Anna Marina, Harrison, Simon J., Miles Prince, H., Ocio, Enrique M., Assadourian, Sylvie, Campana, Frank, Malinge, Laure, Sémiond, Dorothée, van de Velde, Helgi, Yong, Kwee
Publicado 2020

P1366: SAR442257, A CD38/CD28/CD3 TRISPECIFIC ANTIBODY, POTENTIATES CAR T-CELL ACTIVITY AGAINST LARGE B-CELL LYMPHOMA

por Reville, Patrick, Dai, Enyu, Sheikh, Irtiza, Deng, Qing, Henderson, Jared, Le, Cuong, Rojas, Estela, Okwuchi, Chizitara, Wilson, Ashley, Parsons, Sydney, Lockman, Shyanne, Kim, Peter, Bisht, Kamlesh, van de Velde, Helgi, Wang, Hongfang, Neelapu, Sattva, Wang, Linghua, Green, Michael
Publicado 2023

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

por Schjesvold, Fredrik, Richardson, Paul G., Facon, Thierry, Alegre, Adrián, Spencer, Andrew, Jurczyszyn, Artur, Sunami, Kazutaka, Frenzel, Laurent, Min, Chang-Ki, Guillonneau, Sophie, Lin, Peggy L., Le-Guennec, Solenn, Campana, Frank, van de Velde, Helgi, Bensfia, Samira, Bringhen, Sara
Publicado 2021